These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 17558912

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C.
    Gao X, Stephens JM, Carter JA, Haider S, Rustgi VK.
    Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):335-43. PubMed ID: 22812557
    [Abstract] [Full Text] [Related]

  • 24. The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis A.
    Jacobs RJ, Koff RS, Meyerhoff AS.
    Am J Gastroenterol; 2002 Feb; 97(2):427-34. PubMed ID: 11866283
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C.
    San Miguel R, Gimeno-Ballester V, Blázquez A, Mar J.
    Gut; 2015 Aug; 64(8):1277-88. PubMed ID: 25311032
    [Abstract] [Full Text] [Related]

  • 27. Management of chronic hepatitis C.
    Asselah T, Boyer N, Ripault MP, Martinot M, Marcellin P.
    Minerva Gastroenterol Dietol; 2007 Mar; 53(1):9-23. PubMed ID: 17415342
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Factors associated with adherence to combination therapy of interferon and ribavirin for patients with chronic hepatitis C: importance of patient's motivation and physician's treatment experience.
    Tanioka D, Iwasaki Y, Araki Y, Osawa T, Ikeda H, Ando M, Kobashi H, Sakaguchi K, Shiratori Y, Yamamoto K.
    Liver Int; 2009 May; 29(5):721-9. PubMed ID: 19141025
    [Abstract] [Full Text] [Related]

  • 31. [Cost evaluation of therapeutic management of patients with chronic hepatitis C].
    Faure C, Gasser P, Douet MC.
    Therapie; 1997 May; 52(6):553-8. PubMed ID: 9734107
    [Abstract] [Full Text] [Related]

  • 32. Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C.
    Townsend R, McEwan P, Kim R, Yuan Y.
    Value Health; 2011 Dec; 14(8):1068-77. PubMed ID: 22152176
    [Abstract] [Full Text] [Related]

  • 33. Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism.
    Vegter S, Perna A, Hiddema W, Ruggenenti P, Remuzzi G, Navis G, Postma MJ.
    Pharmacogenet Genomics; 2009 Sep; 19(9):695-703. PubMed ID: 19696696
    [Abstract] [Full Text] [Related]

  • 34. Review article: the treatment of hepatitis C virus recurrence after liver transplantation.
    Arjal RR, Burton JR, Villamil F, Rosen HR.
    Aliment Pharmacol Ther; 2007 Jul 15; 26(2):127-40. PubMed ID: 17593060
    [Abstract] [Full Text] [Related]

  • 35. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis.
    Roche B, Sebagh M, Canfora ML, Antonini T, Roque-Afonso AM, Delvart V, Saliba F, Duclos-Vallee JC, Castaing D, Samuel D.
    Liver Transpl; 2008 Dec 15; 14(12):1766-77. PubMed ID: 19025933
    [Abstract] [Full Text] [Related]

  • 36. Living with hepatitis C and treatment: the personal experiences of patients.
    Sgorbini M, O'Brien L, Jackson D.
    J Clin Nurs; 2009 Aug 15; 18(16):2282-91. PubMed ID: 19583661
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Doing battle with HCV.
    Fimmel CJ.
    Am J Gastroenterol; 2000 Mar 15; 95(3):582-3. PubMed ID: 10710043
    [No Abstract] [Full Text] [Related]

  • 39. All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses.
    Hagan LM, Yang Z, Ehteshami M, Schinazi RF.
    J Viral Hepat; 2013 Dec 15; 20(12):847-57. PubMed ID: 24304454
    [Abstract] [Full Text] [Related]

  • 40. Estimation of utilities for chronic hepatitis C from SF-36 scores.
    Thein HH, Krahn M, Kaldor JM, Dore GJ.
    Am J Gastroenterol; 2005 Mar 15; 100(3):643-51. PubMed ID: 15743364
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.